jueves, 12 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

Goldman or Citigroup: Which Transformation Story Is More Compelling?

View original at finance.yahoo.com
Goldman or Citigroup: Which Transformation Story Is More Compelling? Wall Street’s largest institutions are redefining what sustainable growth looks like…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Goldman is targeting high-teens returns for the AWM division and roughly 5% annual growth in long-term fee-based net inflows over the medium term

    80% confidence
  • For investors seeking combination of earnings durability, strategic clarity and long-term upside, GS emerges as more compelling transformation story and stronger stock to own

    80% confidence
  • Asset Management unit intends to expand private credit portfolio to $300 billion by 2029

    80% confidence
  • Citigroup expects revenues to see compounded annual growth rate of 4-5% by 2026-end and will drive $2-2.5 billion of annualized run rate savings

    80% confidence
  • Management continues to target return on tangible common equity of 10-11% in 2026

    80% confidence
  • Goldman offers clearer growth narrative backed by strengthening fundamentals, upward earnings revisions and strategic focus on high-margin, scalable businesses

    80% confidence
  • Citigroup is primarily in repair mode with near-term story revolving around cost cuts, divestitures and capital redeployment rather than organic competitive expansion

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,565 documentos fuente archivados
Consulta estos datos → isubstrate.com
Goldman or Citigroup: Which Transformation Story Is More Compelling? — Source | Via News | es.VIA.NEWS